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Background: Increased oxidative stress and bronchial inflammation are important mechanisms
in the pathophysiology of COPD.
Aim: To investigate whether treatment with the inhaled corticosteroid fluticasone propionate
(FP) or the anti-oxidative agent N-acetylcysteine (NAC) are effective in primary care patients.
Methods: The study was a 3-year placebo-controlled randomised controlled trial preceded by
a 3-month washout and 2-week prednisolone pre-treatment. Patients were (ex-)smokers with
chronic bronchitis or COPD. Interventions were inhaled FP 500 mg b.i.d., oral NAC 600 mg o.d.,
or placebo. Exacerbation rate and quality of life measured with the Chronic Respiratory
Questionnaire (CRQ) were the primary outcomes, FEV1 decline and respiratory symptoms
secondary outcomes.
Results: 286 patients recruited from 44 general practices were randomised. Exacerbation rate
was 1.35 times higher for NAC (pZ 0.054) and 1.30 times higher for FP (pZ 0.095) compared
with placebo. CRQ total scores did not differ between NAC (pZ 0.306) or FP (pZ 0.581) treat-
ment compared to placebo. Annual postbronchodilator FEV1 decline was 64 mL [SD 5.4] for
NAC [pZ 0.569 versus placebo], 59 mL [SD 5.7] for FP [pZ 0.935], and 60 mL [SD 5.4] for
placebo.ctive pulmonary disease; CRQ, Chronic Respiratory Questionnaire; ECSC, European Community for
ry volume in one second; FVC, Forced vital capacity; GOLD, Global Initiative for Chronic Obstructive
r; SD, Standard deviation; 95% CI, Ninety-five percent confidence interval.
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Fluticasone and N-acetylcysteine in COPD 543Conclusion: No beneficial treatment effects for either high-dosed inhaled fluticasone propio-
nate or oral N-acetylcysteine were observed in our study population of patients with COPD or
chronic bronchitis.
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Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality worldwide and the burden
of COPD on society is expected to increase substantially in
forthcoming years.1 Bronchial inflammation and oxidative
stress due to cigarette smoke exposure are important factors
in the pathophysiology of COPD.2 N-acetylcysteine is
a compound with anti-oxidative properties that is believed to
reduce oxidative stress in the lung tissue by replenishing
glutathione levels.3 Thus, treatment with N-acetylcysteine
may alter lung oxidant/antioxidant imbalance and, conse-
quently, reduce respiratory symptoms, exacerbations, and
decline of lung function in patients with COPD.3 Published
meta-analyses of clinical studies have pointed to a protective
effect of N-acetylcysteine on the risk of exacerbations.4e6
However, the studies included in these meta-analyses
generally did not last beyond six months of follow-up and
used the proportion of patients suffering from an exacerba-
tion rather than the actual rate of exacerbations as an
endpoint. The long-term effects of N-acetylcysteine on clin-
ical outcomes and disease progression have recently been
reported from a placebo-controlled trial in patients with
moderate to severe COPD, the so-called ‘Broncus’ study.7 In
this study N-acetylcysteine was ineffective in preventing the
accelerated lung function decline that is typical for COPD,
nor did it prevent the occurrence of exacerbations or improve
quality of life. However, the subgroup of patients who were
not on concomitant inhaled corticosteroid treatment showed
some benefit of N-acetylcysteine in terms of reduced exac-
erbation rate.7
Compared with N-acetylcysteine the long-term effects
of inhaled corticosteroids in COPD have been investigated
more extensively. Inhaled corticosteroids do not seem to be
able to suppress the appropriate type of inflammation in
the airways of patients with COPD.8 Three recent meta-
analyses of published efficacy studies have indicated that
there may be a small effect of regular inhaled corticoste-
roid treatment on lung function decline of 5e8 mL per
year.9e11 The clinical relevance of an effect this size
remains questionable. One of the meta-analyses concluded
that inhaled corticosteroid treatment reduces exacerba-
tions by 30 percent in patients with COPD.11
The aim of the study reported in this paper was to
determine the 3-year effectiveness of regular treatment
with N-acetylcysteine or fluticasone propionate in the
heterogeneous group of current or former smokers with
chronic bronchitis or mild to moderate COPD that is typi-
cally treated in general practice. The effectiveness of
these two drugs has not been studied in a head-to-head
comparison before. Despite the fact that patients with mild
and moderate COPD clearly predominate in the patient
population, published studies so far have concentrated on
patients in the more severe disease stages. As changes inoccurrence of exacerbations and quality of life have gained
importance as study outcomes in clinical COPD research,
the current study was designed to investigate effects on
these outcomes instead of the conventional primary
outcome, rate of lung function decline.
Methods
Study population
Patients were recruited from 44 general practices (study
centres) in the southeastern part of the Netherlands. Trial
inclusion criteria were: age 35e75 years; current or former
smoker; chronic dyspnoea, sputum production and cough
for at least three consecutive months per year during the
previous two years12; postbronchodilator forced expiratory
volume in one second (FEV1) <90% of the predicted value,
and/or postbronchodilator FEV1/FVC (forced vital capacity)
of the predicted value <88% for men and <89% for
women.12 Main exclusion criteria were a postbronchodilator
FEV1 <40% of predicted and/or a history of asthma, allergic
rhinitis, or allergic eczema. Patient inclusion ran from
December 1998 to January 2001. The medical ethics review
committees of the four hospitals involved approved the
study and all patients gave written informed consent.
Trial design and sample size
The study was designed as a randomised, double blind,
double dummy, placebo-controlled phase IV trial with two
active treatment groups, N-acetylcysteine and fluticasone
propionate. An independent statistician generated a ran-
domisation list based on a block size of three for treatment
allocation to balance the three treatment arms by study
centre. Neither investigators nor patients were aware of the
group assignment. The trial was preceded by (in chronolog-
ical order): an optional smoking cessation attempt supported
by the GP in trial candidates who were current smokers; a
3-months washout phase to eliminate possible carry-over
effects of a successful smoking cessation attempt or the
withdrawal of prior treatment with N-acetylcysteine and/or
inhaled corticosteroids; and a 14-days pre-treatment phase
(30 mg oral prednisolone o.d.) in order to attain the highest
possible baseline condition. The prespecified primary
outcomes of the study were the rate of exacerbations and
disease-specific quality of life as assessed with the inter-
viewer-administered version of the Chronic Respiratory
Questionnaire (CRQ).13 These outcomes were considered
equally relevant and equally suitable as primary outcomes,
a presumption that was later confirmed by other authors.14
Thus, we performed separate power calculations for both
outcomes. Based on previous studies in patients with COPD
the average rate of exacerbations in a three year time frame
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tion of one exacerbation in three years time as a clinically
relevant treatment effect. Assuming a Poisson distribution,
the standard deviation was O3Z 1.73. With alphaZ 0.05, 1-
betaZ 0.80 and a 30% rate of non-informative (i.e., because
of dying or lost-to-follow-up) dropout rate the required
number of patients was 207 (69 per treatment arm). A 0.5
point difference in the total CRQ score (which is considered
to be the minimally important difference for this instru-
ment), a standard deviation of the difference in total CRQ
score of 1.0,17 and the same assumptions for alpha, 1-beta
and dropout rate, the required number of patients was 270
(90 per treatment arm). The latter number was taken as the
minimal number of patients to be randomised.
Interventions and measurements
Trial medication consisted of either fluticasone propionate
(GlaxoSmithKline, Zeist, The Netherlands) 500 mg twice
daily administered as dry powder inhalation by Diskus
inhaler, oral N-acetylcysteine (Zambon Group, Amersfoort,
The Netherlands) administered as 600 mg effervescent
tablets dissolved in a glass of tap water taken once daily in
themorning, ormatching placebo treatment. The dosages of
trial medication were chosen on the basis of reported
efficacy data from previous trials on treatment with inhaled
steroids and N-acetylcysteine in COPD.6,18,19 In addition, the
choice for the dose of 600 mg N-acetylcysteine was
conferred with the Broncus7 investigators. Patients were
considered compliant if they had taken 80% or more of both
their effervescent tablets and inhalations. Patients in whom
the blinded trial medication had been withdrawn by the GP,
either for medical reasons or due a patients’ lack of moti-
vation to continue its use, were considered as ‘dropouts’.
Patients visited their general practice every 3 months
and the lung function laboratory every 12 months until the
end of the trial period. Patients were instructed to contact
or visit their GP in case of worsening of their respiratory
symptoms. An exacerbation was defined as an episode with
one or more subsequent unscheduled contacts with either
a GP or a chest physician due to worsening of respiratory
symptoms. In case no course of prednisolone and/or anti-
biotics was prescribed, the exacerbation was labelled as
‘mild’; exacerbations treated with prednisolone and/or
antibiotics were labelled as ‘moderate’, exacerbations
leading to an emergency room visit or hospitalization as
‘severe’. Apart from the exacerbation data recorded by the
GPs, patients themselves kept a study calendar to report
episodes with aggravated respiratory symptoms (dyspnoea,
cough, phlegm) and/or increased bronchodilator use. An
episode was defined as 3 consecutive days with aggra-
vated symptoms with an interval of >7 days since the
previous episode. An episode ended when symptoms had
returned to their normal level and no additional broncho-
dilator puffs were reported anymore. The analysis of
calendar data should be considered as a secondary analysis.
After the trial, all prescriptions for bronchodilators and
other respiratory medication were collected from patients’
general practice and pharmacy records.
The CRQ is a 20-item instrument which measures four
domains: activity related dyspnoea; fatigue; emotional
function; and mastery. Answers are scored on a seven-pointscale ranging from 1 (maximum impairment) to 7 (no
impairment). Participants completed the CRQ during the
annual laboratory visits. General practice staff was appro-
priately trained in spirometry before the start of the study.
Practices and laboratories were all equipped with an elec-
tronic spirometer (Microloop II; MicroMedical Ltd,
Rochester, UK) and spirometry software (Spirare; Diag-
nostica Ltd, Oslo, Norway). Spirometry was performed
according to European Respiratory Society standards.20 Both
in the laboratories and the study centres spirometry tests
were conducted before and 15 min after administration of
400 mg salbutamol by metered-dose inhaler and Volumatic
spacer as a part of all scheduled visits. ECSC reference
equations20 were used to calculate FEV1 % predicted values.
Respiratory symptoms (dyspnoea, cough, phlegm) were
measured on a 7-point Likert scale21 during the 3-monthly
visits to the general practice, a higher score indicating less
serious symptoms.
Statistical analysis
The primary analyses were done on an intention-to-treat
basis. Additional per protocol analyses were done on
patients with a trial medication compliance rate 80%.
Hypothesis testing was two-sided; p< 0.05 was defined as
statistically significant. Covariates included in all regression
models to adjust for potential confounding were: gender,
age, and baseline postbronchodilator FEV1 % predicted,
smoking status and number of packyears. We used a corre-
lated time-event model with an overdispersion parameter
included (GENMOD-procedure in SAS, Statistical Analysis
System) to test differences in exacerbation rates between
fluticasone or N-acetylcysteine and placebo.22,23 Results
are reported as weighed mean and median rates, and as
Rate Ratios (RR) for an exacerbation in the N-acetylcys-
teine or the fluticasone group relative to placebo (RR< 1
indicating a prophylactic effect of N-acetylcysteine or
fluticasone). Effects on quality of life were analysed using
repeated measurements regression analysis (MIXED-proce-
dure in SAS) on CRQ total and domain scores. Repeated
measurements regression models with the same covariates
were used to analyse differences in the yearly FEV1 and FVC
decline and respiratory symptoms as determined during the
3-monthly general practice visits.
Results
Patient demographics, dropout and treatment
compliance
Table 1 shows the baseline characteristics of the three
treatment groups. Following the GOLD classification,24 22%
of all patients suffered from chronic bronchitis without
obstruction, 14% from mild, 47% from moderate, and 17%
from severe COPD. Dropout of study candidates during the
pre-trial phase has been reported elsewhere25 but is
summarized in Fig. 1. Overall dropout rate during the trial
was 43% and was not different for N-acetylcysteine, fluti-
casone, or placebo (pZ 0.790). Average time to dropout
was 318 [SD 314] days and was similar for the three treat-
ment groups (pZ 0.828). Fig. 2 shows the course of the
Table 1 Baseline characteristics of the randomised population. Figures are means (SD) unless stated otherwise.
N-acetylcysteine Placebo Fluticasone
N 96 96 94
Gender, males (%) 75 (78) 65 (68) 69 (73)
Age, years 59.2 (9.2) 59.6 (10.1) 58.4 (9.9)
Body mass index, kg m2 26.5 (4.0) 26.0 (4.6) 26.5 (4.6)
Smoking history, packyears 28.0 (17.5) 26.5 (16.7) 30.2 (18.2)
Smoking status, current smokers (%) 54 (56) 49 (51) 58 (62)
Cigarettes, current number per daya 8.6 (10.1) 8.1 (10.7) 10.4 (12.0)
Bronchodilators, number (%)b
No bronchodilator 22 (23) 23 (24) 24 (26)
Short-actingc 56 (58) 53 (55) 51 (54)
Long-acting or theophyllined 18 (19) 20 (21) 19 (20)
Inhaled corticosteroidse 43 (45) 51 (53) 37 (39)
N-acetylcysteine 5 (5) 2 (2) 5 (5)
Pulmonary function
Prebronchodilator FEV1 (mL) 1929 (624) 2010 (717) 1919 (608)
as % predicted 61.7 (14.5) 65.7 (17.7) 63.2 (17.1)
Prebronchodilator FVC (mL) 3135 (922) 3191 (996) 3154 (950)
Prebronchodilator FEV1/FVC 61.7 (11.2) 63.1 (12.4) 61.8 (12.2)
Postbronchodilator FEV1 (mL) 2136 (643) 2179 (715) 2087 (604)
as % predicted 68.1 (13.9) 71.4 (17.1) 68.7 (15.7)
Postbronchodilator FVC (mL) 3471 (974) 3427 (972) 3398 (876)
Postbronchodilator FEV1/FVC 61.7 (11.0) 63.9 (12.6) 62.1 (11.8)
Reversibility, as % predicted FEV1 6.8 (5.4) 6.1 (4.5) 5.9 (5.3)
Disease severityf (%)
At risk 18 25 22
Mild 13 15 14
Moderate 53 40 48
Severe 16 20 16
Response on prednisolone pre-treatment
Prebronchodilator FEV1 (mL) 87 (251) 62 (220) 31 (218)
as % predicted 3.0 (8.7) 2.3 (7.4) 1.2 (7.5)
Postbronchodilator FEV1 (mL) 97 (195) 84 (214) 50 (192)
as % predicted 3.2 (6.7) 3.0 (7.0) 1.9 (6.7)
Yearly exacerbation rate
mean (SD) number/year 0.87 (0.75) 0.90 (0.81) 0.86 (0.80)
median (IQR) number/year 0.5 (1.0) 0.5 (1.0) 0.5 (1.5)
Quality of life
CRQ e Total score 4.83 (1.04) 4.84 (1.11) 4.73 (1.00)
CRQ e Dyspnoea 4.55 (1.32) 4.59 (1.48) 4.59 (1.48)
CRQ e Fatigue 4.54 (1.10) 4.66 (1.24) 4.31 (1.22)
CRQ e Emotional function 4.82 (1.13) 4.83 (1.24) 4.72 (1.05)
CRQ e Mastery 5.47 (1.27) 5.33 (1.32) 5.33 (1.26)
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; SD: standard deviation; IQR: inter quartile range; CRQ: Chronic
Respiratory Questionnaire.
a Including patients who reported to be a non-smokers at the time of trial entry.
b At the start of the washout phase.
c Short-acting b2-agonist, short-acting anticholinergic, or the combination of both.
d Long-acting b2-agonist and/or theophylline, with or without additional short-acting bronchodilator.
e At the time of the screening visit to the general practice.
f Classification according to Global Initiative on Obstructive Lung Disease (GOLD) criteria (2001).
Fluticasone and N-acetylcysteine in COPD 545
546 T. Schermer et al.respiratory related dropout, whereas Table 2 shows the
characteristics of dropouts compared with completers.
After dropout from the trial, 10 [10.4% of all] patients
assigned to N-acetylcysteine, 15 [15.1%] patients assigned
to placebo, and 10 [10.6%] patients assigned to fluticasone
received one or more prescriptions for an inhaled cortico-
steroid from their GP or chest physician. Twelve patients
(one N-acetylcysteine, three placebo, and eight fluticasone
treated patients) died during the trial, myocardial infarc-
tions (4 patients) and lung carcinoma (3 patients) being the
most frequent causes of death. There were no statistically
significant differences in the self-reported changes in
smoking status or the daily number of cigarettes smoked
between the three groups. On average, patients used 64.1
[SD 38.5] percent of their effervescence tablets and 61.9
[SD 37.7] of their dry powder inhalations. No significant
differences in the use of tablets or inhalations between the
treatment groups were observed. The average number of
prescriptions for short-acting bronchodilators was 9.4 forFigure 1 Profile of number of patients and dropout during each p
are reported elsewhere.20 )proportion of the total patient populati
one reason. zeither use of inhaled steroids or N-acetylcysteine as m
how to use the trial medication.fluticasone, 8.3 for N-acetylcysteine, and 7.2 for placebo.
For long-acting bronchodilators these numbers were 2.8,
2.7, and 3.3 prescriptions, respectively.
Clinical effects
The total number of GP reports of exacerbations was 751.
Most exacerbations [84.3%] were of moderate severity (i.e.,
were treated with a short course of prednisolone and/or
antibiotics). Especially in the N-acetylcysteine and flutica-
sone groups the distribution of exacerbation rate was
skewed due a small number of distinct outliers (Fig. 3).
Table 3 shows the mean and median yearly exacerbation
rates in the three groups and the rate ratios for N-
acetylcysteine and fluticasone compared to placebo. With
a mean rate of 0.73 [95% CI 0.58; 0.89] exacerbations per
year the lowest rate was observed in the placebo group.
N-acetylcysteine treated patients showed 1.35 times higher
exacerbation rates than placebo treated patientshase of study. Details of withdrawals during the washout phase
on screened. ytrial candidates could be ineligible for more than
aintenance treatment during the trial, or failing to comprehend
Figure 2 Course of respiratory related dropout in the three
study groups.
Fluticasone and N-acetylcysteine in COPD 547(pZ 0.054). The corresponding figure for fluticasone was
1.30 (pZ 0.095). Median exacerbation rates were much
lower and very similar for the three treatment groups
(Table 3), which illustrates the influence of the outliers in
the N-acetylcysteine and fluticasone groups on the mean
overall results. 77% of all patients produced valid study
calendar registrations for at least one month of follow-up.
The mean number of calendar months registered was 23.1
[SD 14.0] for N-acetylcysteine, 24.7 [SD 12.1] for flutica-
sone, and 24.9 [SD 12.3] for placebo. The number of
episodes with aggravated symptoms extracted from theTable 2 Characteristics of study dropouts and completers.
N-acetylcysteine
Dropoutsa Completers
N 44 52
Gender, males (%) 34 (77) 41 (79)
Age, years 56.4 61.5
Body mass index, kg m2 26.5 26.6
Smoking history, packyears 26.6 29.2
Smoking, current smokers (%) 28 (64) 26 (50)
Inhaled corticosteroidsb 23 (52) 20 (38)
N-acetylcysteine 2 (4) 3 (6)
Lung function
Prebronchodilator FEV1 (mL) 1987 1879
as % predicted 61.5 61.9
Postbronchodilator FEV1 (mL) 2197 2084
as % predicted 68.0 68.2
Postbronchodilator FEV1/FVC 61.6 61.7
Mean exacerbation rate/yearc 0.82 0.92
FEV1: forced expiratory volume in one second; FVC: forced vital capa
a Dropout: no longer on trial medication.
b at the time of screening for trial eligibility.
c in the two year period preceding the screening visit.calendar data was 3.5 [SD 4.6] per year for N-acetylcys-
teine, 3.1 [SD 3.9] for fluticasone, and 3.3 [SD 3.9] for
placebo (pZ 0.768).
The analysis of the changes in quality of life showed
improvements in the total CRQ score in all three treatment
groups, especially in the first year of the study (Fig. 4). No
statistically significant differences for either N-acetylcys-
teine or fluticasone relative to placebo were observed
(pZ 0.306 and pZ 0.581, respectively). Mean CRQ scores
never exceeded the 0.5 units threshold for the minimum
clinically important difference. None of the four CRQ
domain scores showed statistically significant improve-
ments in favour of N-acetylcysteine or fluticasone.
Fig. 5 shows that the course of the postbronchodilator
FEV1 in the N-acetylcysteine and fluticasone groups paral-
leled the course in the placebo group, except for the
(expected) initial difference in the fluticasone group in
the first three months after randomisation. Table 4 shows
the crude and adjusted yearly FEV1 decline for the total
trial period. For the postbronchodilator FEV1 the decline
was lowest in the fluticasone group (47 mL [SE 6]), followed
by the N-acetylcysteine and placebo groups (52 mL [SE 6]
and 53 mL [SE 6], respectively). No statistically significant
differences in favour of either N-acetylcysteine or flutica-
sone were observed for the FEV1. A similar pattern
was recorded for the decline of the FVC (Table 4), the
fluticasone group showing the lowest decline for the
prebronchodilator as well as the postbronchodilator FVC
values. For the prebronchodilator FVC decline the differ-
ence between fluticasone and placebo treatment approxi-
mated the level of statistical significance (pZ 0.061).
Although symptom scores for phlegm and cough (but not
dyspnoea scores) seemed to improve in the fluticasone
group during the first 6 months, no statistically significantPlacebo Fluticasone
Dropoutsa Completers Dropoutsa Completers
40 56 39 55
21 (52) 44 (79) 30 (79) 39 (70)
59.7 59.6 59.0 58.0
25.6 26.4 26.7 26.5
27.6 25.6 32.1 28.9
26 (46) 23 (57) 25 (66) 33 (59)
26 (65) 25 (44) 12 (31) 25 (45)
0 (0) 2 (4) 4 (10) 1 (2)
1773 2179 1848 1966
61.6 68.6 60.3 65.2
1940 2350 2056 2108
67.4 74.2 66.8 69.9
61.4 65.7 61.3 62.7
0.99 0.84 0.74 0.94
city.
Figure 3 Distribution of exacerbation rates by treatment
group. The figures above each bar indicate numbers of
patients.
Figure 4 Change in quality of life according to the Chronic
Respiratory Questionnaire (CRQ) during the trial. Vertical bars
are standard errors. The dotted line indicates the threshold for
a clinically meaningful change. N-acetylcysteine versus
placebo: pZ 0.306; and Fluticasone propionate versus
placebo: pZ 0.581.
548 T. Schermer et al.differences in symptom scores between the study groups
were found for the total trial period.
Discussion
In this general practice based long-term head-to-head
comparison of anti-oxidative and anti-inflammatory main-
tenance treatment we observed that neither treatment
with 600 mg of oral N-acetylcysteine nor 1000 mg of inhaled
fluticasone per day seemed to affect the long-term course
of respiratory quality of life nor exacerbations rate in
a heterogeneous study population of (ex-)smokers with
chronic bronchitis or mild to moderately severe COPD.
Although the higher exacerbation rates in the N-acetylcys-
teine or fluticasone groups may be misinterpreted as
‘deleterious’ effects of these treatments, this finding is
explained by the fact that a small number of patients in the
two active treatment groups experienced very frequent
exacerbations. Analysis of the secondary outcomes showed
no differences in the decline of the FEV1 and FVC, respi-
ratory symptoms, or time to dropout for either N-ace-
tylcysteine or fluticasone.
With the current insights in the pathophysiology of
COPD24 our trial population can be characterized as
a heterogeneous group of middle-aged (ex-)smokers with
chronic bronchitis, who either showed incipient airflow
obstruction or had established mild to moderateTable 3 Yearly exacerbation rates and rate ratios for N-acetylc
N-acetylcysteine
(nZ 96)
Placebo
(nZ 96)
Meanc
(95% CI)
Median Meanc
(95% CI)
Median
Intention-
to-treat
1.00
(0.77; 1.24)
0.67 0.73
(0.57; 0.88)
0.65
Per protocolb 0.84
(0.48; 1.19)
0.38 0.51
(0.33; 0.70)
0.32
a Interpretation: number of times per year that patients in an ac
exacerbated more often than patients in the placebo group. For exa
patients was 1.35 times higher than for placebo.
b Patients with 80% treatment compliance for both the inhalers a
c Weighed mean.obstruction. We deliberately did not exclude patients with
reversibility of airflow obstruction from the trial, because
we considered bronchodilator responsiveness to be
a continuous variable in COPD. In the mean time, the
rightness of this presumption has been demonstrated by
other investigators.26 As a consequence, the composition of
our study population was rather different from previous
long-term follow-up studies on the effects of N-acetylcys-
teine7 and inhaled corticosteroids.14,18,19,27e29
Assessment of respiratory health status is increasingly
recognized as an important additional measurement in
patients with COPD and is a better predictor of future
admission to hospital and death than FEV1 is, at least in
patients with severe COPD.30 Compared with previous
studies in patients with more severe COPD,17,31 the baseline
CRQ scores in our study showed a rather low level of
baseline impairment. Obviously, this limited the room for
a relevant therapeutic effect on quality of life for both
active treatment groups. This argumentation also applies toysteine and fluticasone relative to placebo.
Fluticasone
(nZ 94)
Rate ratioa
(p value)
Meanc Median
(95% CI)
N-acetylcysteine
versus
placebo
Fluticasone
versus
placebo
0.93
(0.71; 1.14)
0.67 1.35
(0.054)
1.30
(0.095)
0.69
(0.42; 0.95)
0.35 1.58
(0.099)
1.39
(0.204)
tive treatment group (N-acetylcysteine, fluticasone propionate)
mple: the yearly exacerbation rate for N-acetylcysteine treated
nd effervescent tablets.
Figure 5 Decline of the postbronchodilator FEV1 in the three
treatment groups.
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Fluticasone and N-acetylcysteine in COPD 549the room for improvement on exacerbations: the average
exacerbation rate in the two years preceding the trial was
0.9 exacerbations per year, which is lower than the rates
reported from studies in secondary care COPD patients
from our country32,33 and elsewhere.14,34
A substantial number of patients were treated with an
inhaled corticosteroid and/or N-acetylcysteine by their GP
or chest physician at the time of enrolment in the study. In
order to establish their eligibility for the trial, these
patients had to withstand a washout period of at least three
months. It cannot be ruled out that patients with a good
treatment response on either N-acetylcysteine or inhaled
corticosteroids withdrew their involvement before or
during the washout phase that preceded the trial because
of worsening of their respiratory condition. Previous reports
on withdrawal of inhaled corticosteroid treatment in
COPD32,35e37 imply that this has probably played a role in
our study as well. If this selective dropout of patients with
a good treatment response has indeed occurred, this may
have produced an underestimation of the actual treatment
effects of N-acetylcysteine and fluticasone.
Our observations are not in line with the conclusions of
the published meta-analyses4e6 that N-acetylcysteine
reduces the risk of exacerbation in COPD. Although the
Broncus investigators7 showed no beneficial effect of
N-acetylcysteine on exacerbations in their main analysis,
subgroup analysis on the patients who were not on
concomitant inhaled steroid treatment (w30% of the total
study population) suggests that there may be such
a prophylactic effect in the absence of this anti-inflam-
matory treatment. In our study concomitant use of inhaled
corticosteroids was not permitted unless a patients had
dropped out, in which case the GP could introduce (or
reintroduce) this treatment. Although eventually this
occurred in only 13% of the patients in the N-acetylcysteine
group and 17% in the placebo group, we did not observe
a similar treatment effect in favour of N-acetylcysteine as
the Broncus investigators did.
In contrast with the findings from the Broncus trial7 no
effect of N-acetylcysteine on the vital capacity was seen in
the current study. Although measurement of functional
residual capacity (FRC) was part of the baseline assessment
in the lung function laboratory, this measurement was not
repeated during the subsequent yearly visits to the labo-
ratory. Thus, we could not look at possible changes in FRC
550 T. Schermer et al.like the Broncus investigators did. It should be noted that
the effects on these secondary outcomes in Broncus were
predominantly in patients with severe COPD (GOLD stage
III),24 a group that comprises less than 25% of all diagnosed
COPD patients38 and 16% of our trial population.
Wedidnot observea treatmenteffect offluticasone inour
study population that existed of primary care patients with
predominantly mild to moderate disease. In our view, the
apparent lack of an effect by fluticasone in our study further
supports the recommendations in current COPD guidelines
that inhaled corticosteroids should be reserved for patients
with severe COPD e i.e., patients with an FEV1 below 50% of
the predicted value and frequent exacerbations.24,39
The consistent increase of the CRQ scores over time in
all three treatment groups was salient and unexpected. Our
explanation for this observation is that it was caused by an
‘in-study effect’ e i.e., was the consequence of the rather
intense periodic monitoring of patients as a necessary part
of their trial participation. Although previous placebo-
controlled studies have shown beneficial effects of fluti-
casone treatment on quality of life measurements,14,34 we
did not observe this in our study. Again, this may have been
caused by the limited room for improvement in this
particular study population.
The size of our trial population was not sufficient to
establish effects on lung function decline by N-acetylcys-
teine or fluticasone treatment with an acceptable level of
statistical power. Nonetheless, several spirometric indices
(FEV1 and FVC being the most important ones) were
repeatedly measured and studied as secondary outcomes.
The results showed that apart from the initial increase of
the FEV1 in the fluticasone group during the first months
after randomisation that has also been reported in other
inhaled corticosteroid trials,14,28 the further decline of
FEV1 did not significantly differ between the treatment
groups. The observed small difference in favour of flutica-
sone treatment was of the same magnitude (6 mL) that has
been reported in recent meta-analyses on inhaled cortico-
steroid treatment in COPD.9e11
As expected and in line with previous long-term studies in
patients with COPD,14,19 dropout during the trial was
substantial (43% overall). Although the number of dropouts,
time to dropout, and reasons for dropout did not differ
between the study groups, there was a salient difference in
the number of deaths during the trial: one for N-acetylcys-
teine, three for placebo, and eight for fluticasone treat-
ment. Closer examination of the causes of death in these
patients did not give cause for a suspected association
between fluticasone treatment and a higher mortality risk.
In conclusion, in thisprimarycare studywedidnotobserve
beneficial treatment effects for either the anti-oxidative
drug N-acetylcysteine or anti-inflammatory treatment with
high-dosed inhaled fluticasone in patients with mild to
moderate COPD or chronic bronchitis. This supports recom-
mendations in current COPD guidelines that a beneficial role
ofN-acetylcysteine in the treatment ofCOPD is not supported
by evidence, and that prescription of inhaled corticosteroids
is only supportedbyevidence for patientswith severedisease
and patients with frequent exacerbations. In our study, both
groupswere underrepresentede as is usual in primary caree
which could explain the absence of beneficial effects.
Subgroup analyses of our heterogeneous patient populationmay reveal differential effects of anti-oxidative or anti-
inflammatory treatment in this patient population.
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